Utilizing diversity-oriented synthesis in antimicrobial drug discovery

Future Med Chem. 2014;6(17):1927-42. doi: 10.4155/fmc.14.111.

Abstract

The development of resistance to existing antimicrobials has created a threat to human health that is not being addressed through our current drug pipeline. Limitations with the use of commercial vendor libraries and natural products have created a need for new types of small molecules to be screened in antimicrobial assays. Diversity oriented synthesis (DOS) is a strategy for the efficient generation of compound collections with a high degree of structural diversity. Diversity-oriented synthesis molecules occupy the middle ground of both complexity and efficiency of synthesis between natural products and commercial libraries. In this review we focus upon the use of diversity-oriented synthesis compound collections for the discovery of new antimicrobial agents.

Keywords: Trypanosoma cruzi; chemical complexity; diversity-oriented synthesis; drug discovery; hepatitis C virus; infectious disease; malaria; orthopoxviruses.

Publication types

  • Review

MeSH terms

  • Anti-Infective Agents / chemistry*
  • Anti-Infective Agents / pharmacology
  • Anti-Infective Agents / therapeutic use
  • Biological Products / chemistry
  • Biological Products / pharmacology
  • Biological Products / therapeutic use
  • Communicable Diseases / drug therapy
  • Drug Evaluation, Preclinical
  • Gram-Positive Bacteria / drug effects
  • High-Throughput Screening Assays
  • Humans
  • Orthopoxvirus / drug effects
  • Plasmodium falciparum / drug effects
  • Small Molecule Libraries / chemistry
  • Small Molecule Libraries / pharmacology
  • Small Molecule Libraries / therapeutic use
  • Trypanosoma cruzi / drug effects

Substances

  • Anti-Infective Agents
  • Biological Products
  • Small Molecule Libraries